Shilpa Medicare Limited has appointed Dr. Uday N. Harle as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, its wholly owned subsidiary. The appointment takes effect on August 03, 2026, marking a strategic leadership addition to the company's biologics division. This move aims to leverage Dr. Harle's extensive experience in the global biopharmaceutical sector to drive growth and operational efficiency within the subsidiary.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. Ritu Tiwary, Company Secretary and Compliance Officer, signed the disclosure on August 03, 2026. The appointment was communicated to the BSE Limited and National Stock Exchange of India Ltd.

Dr. Uday N. Harle brings approximately 24 years of experience in the global biopharmaceutical industry. His expertise includes over 18 years in biologics and biosimilars and more than 14 years in leadership roles across research and development, clinical development, regulatory affairs, manufacturing, commercialization, and business management. He holds a Ph.D. in Pharmaceutical Sciences from Nagpur University (RTM Nagpur University) and a Master of Science in Pharmacy. Additionally, he holds Post-Graduate Diplomas in Business Management and Marketing Management from IGNOU.

Appointment Overview

The key details of Dr. Harle's appointment are summarised below:

Professional Background

Dr. Harle's most recent assignment was as Chief Business Officer at Artemis Medicare Services Limited and Premedium Pharma (Apollo Group). Prior to this role, he served as Assistant Vice President & Global Head - Clinical Development at Amneal Group / Kashiv Biosciences. His career also includes tenure as Global Head - Clinical Development at Abbott and Associate Director & R&D Head at Ferring Pharmaceuticals. He has held key positions with Bharat Serums & Vaccines, Sun Pharma, and other leading pharmaceutical organizations.

His expertise spans the entire biologics value chain, including portfolio strategy, research and development, CMC, clinical development, regulatory approvals, manufacturing, commercialization, CDMO partnerships, and P&L management. He possesses significant global regulatory experience, having worked extensively with agencies including the USFDA, EMA, MHRA, Health Canada, and CDSCO. Dr. Harle has contributed to the development of more than 10 biosimilars and over 5 novel biologics, including multiple IND and BLA submissions. His experience also covers peptides, recombinant proteins, cell therapies (including CAR-T), and medical devices.

Dr. Harle has authored approximately 40 scientific publications, published 2 books, and holds 2 patents. He has received several industry awards recognizing his contributions and excellence in biopharmaceutical research and development.

Dr. Sridevi Khambhampaty has resigned as Chief Executive Officer of Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare Limited , effective from the closing hours of July 15, 2026. The resignation was submitted via a letter dated April 15, 2026, and is attributed to personal commitments.

The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that the requisite details regarding the change in senior managerial personnel have been provided as per the regulations.

Resignation Details

The following table outlines the key details regarding the change in leadership at the material subsidiary:

Shilpa Biologicals Private Limited operates as a material subsidiary of Shilpa Medicare Limited. The outgoing CEO expressed her best wishes for the company's future in the biologics business.